MedTrace Logo

a Retrospective Study on the Systemic Treatment of LPP and FFA

NCT06512766 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2024-07-22

No results posted yet for this study

Summary

This retrospective study aims to assess the effectiveness of systemic treatments for lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) in patients treated at the Erasmus MC University Medical Center. LPP and FFA are chronic inflammatory hair disorders leading to irreversible hair loss. The study evaluates treatment responses to systemic medications, including hydroxychloroquine, methotrexate, cyclosporine A, and retinoids.

Conditions

  • Cicatricial Alopecia
  • Lichen Planopilaris
  • Lichen Plano-Pilaris
  • Frontal Fibrosing Alopecia
  • Hair Diseases
  • Scarring Alopecia
  • Hair Loss/Baldness

Interventions

DRUG

Hydroxychloroquine

Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Methotrexate

This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Cyclosporine A

Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Retinoids

This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

Sponsors & Collaborators

Principal Investigators

  • DirkJan Hijnen, MD, PhD · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-23
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06512766 on ClinicalTrials.gov